Back to Journals » Cancer Management and Research » Volume 11

Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges

Authors Martin Huertas R, Saavedra Serrano C, Perna C, Ferrer Gómez A, Alonso Gordoa T

Received 25 August 2018

Accepted for publication 21 January 2019

Published 16 May 2019 Volume 2019:11 Pages 4541—4548

DOI https://doi.org/10.2147/CMAR.S185202

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 4

Editor who approved publication: Dr Xueqiong Zhu


Video abstract presented by Roberto Martin Huertas.

Views: 31

Roberto Martin Huertas,1 Cristina Saavedra Serrano,1 Cristian Perna,2 Ana Ferrer Gómez,2 Teresa Alonso Gordoa1

1Medical Oncology Department, Universitary Hospital Ramon y Cajal, Madrid, Spain; 2Pathology Department, Universitary Hospital Ramon y Cajal, Madrid, Spain

Abstract: Immune checkpoint inhibitors have revolutionized cancer treatment due to their undeniable efficacy, but a range of new adverse events (AE) has emerged. In particular, cardiac toxicity is a potentially fatal AE, and introduces new challenges regarding its underlying molecular mechanisms of occurrence, optimal treatment and follow up, and prevention. We present a clinical case of a patient with advanced kidney cancer treated with nivolumab as a third line treatment. After four cycles, the patient developed nonspecific symptoms and was hospitalized, identifying a set of clinical, analytical and electrocardiographic alterations compatible with myocarditis. Despite the intensive support, the patient died and a necropsy study was performed. We present a detailed description of the clinical case including the pathological and molecular findings, and we conduct a review of the available evidence related to immune-mediated cardiac toxicity to offer some new highlights in the management of this AE.

Keywords: myocarditis, nivolumab, kidney, immune-related adverse events

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]